2014 Korean Liver Cancer Study Group-National Cancer Center Korea Practice Guideline for the Management of Hepatocellular Carcinoma
Open accessThe DOI matches its Crossref record; 367 of the 367 references it cites were found in a registry or an index.
Abstract
The guideline for the management of hepatocellular carcinoma (HCC) was first developed in 2003 and revised in 2009 by the Korean Liver Cancer Study Group and the National Cancer Center, Korea. Since then, many studies on HCC have been carried out in Korea and other countries. In particular, a substantial body of knowledge has been accumulated on diagnosis, staging, and treatment specific to Asian characteristics, especially Koreans, prompting the proposal of new strategies. Accordingly, the new guideline presented herein was developed on the basis of recent evidence and expert opinions. The primary targets of this guideline are patients with suspicious or newly diagnosed HCC. This guideline provides recommendations for the initial treatment of patients with newly diagnosed HCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–367 of 367
Pawlik, T. M. (2005) · Archives of Surgery · doi:10.1001/archsurg.140.5.450 · Cited by 224 · cited 1×
“Therefore, the resectability for HCC should not be decided upon according to tumor size (125-127).”
BackgroundLencioni, R., Kudo, M., Ye, S. ‐., Bronowicki, J. ‐., Chen, X. ‐., Dagher, L., Furuse, J., Geschwind, J. F., Guevara, L. L., Papandreou, C., et al. (2014) · International Journal of Clinical Practice · doi:10.1111/ijcp.12352 · Cited by 223 · cited 1×
“In clinical practice, the safety and efficacy of sorafenib are reported to be comparable between Child-Pugh class A and B patients (379-382); however, the prognosis is reported to differ with respect to the presence of ascites and Child-Pugh score (383).”
BackgroundYoon, S. M., Lim, Y.-S., Won, H. J., Kim, J. H., Kim, K. M., Lee, H. C., Chung, Y.-H., Lee, Y. S., Lee, S. G., Park, J.-H., et al. (2012) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2011.03.019 · Cited by 223 · cited 1×
“An advantage of EBRT is that it can be performed safely regardless of the presence of portal vein invasion by the tumor (330-344).”
BackgroundDecaens, T., Roudot‐Thoraval, F., Bresson‐Hadni, S., Meyer, C., Gugenheim, J., Durand, F., Bernard, P., Boillot, O., Boudjema, K., Calmus, Y., et al. (2005) · Liver Transplantation · doi:10.1002/lt.20418 · Cited by 222 · cited 1×
“Many studies report survival rates similar to those of untreated individuals (191-194); however, the major limitation of these studies is shorter waiting times (< 6 months) for LT (191, 192).”
ResultLee, H., Kim, J. S., Choi, I. J., Chung, J. W., Park, J. H., & Kim, C. Y. (1997) · PubMed · Cited by 221
Shetty, K., Timmins, K., Brensinger, C., Furth, E. E., Rattan, S., Sun, W., Rosen, M., Soulen, M., Shaked, A., Reddy, R. K., et al. (2004) · Liver Transplantation · doi:10.1002/lt.20140 · Cited by 219 · cited 1×
“Major risk factors for recurrence after transplantation are tumor size and vascular invasion; other risk factors include tumor number, degree of differentiation, serum AFP level, and bilobar location of tumors (508-510).”
BackgroundWu, C.-C., Ho, Y.-Z., Ho, W. L., Wu, T.-C., Liu, T.-J., & P'Eng, F.-K. (1995) · Journal of British Surgery · doi:10.1002/bjs.1800820141 · Cited by 218 · cited 1×
“Transarterial chemoembolization (TACE), performed before hepatic resection for the purpose of improving postoperative prognosis, is not recommended (110, 111).”
BackgroundValla, D.-C., Chevallier, M., Marcellin, P., Payen, J.-L., Trepo, C., Fonck, M., Bourliere, M., Boucher, E., Miguet, J.-P., Parlier, D., et al. (1999) · Hepatology · doi:10.1002/hep.510290616 · Cited by 211 · cited 1×
“However, others reported no significant difference in HCC incidence between treated and untreated controls (28).”
BackgroundMalagari, K., Pomoni, M., Moschouris, H., Bouma, E., Koskinas, J., Stefaniotou, A., Marinis, A., Kelekis, A., Alexopoulou, E., Chatziioannou, A., et al. (2012) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-012-0394-0 · Cited by 208
Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma
Zimmerman, M. A., Trotter, J. F., Wachs, M., Bak, T., Campsen, J., Skibba, A., & Kam, I. (2008) · Liver Transplantation · doi:10.1002/lt.21420 · Cited by 206 · cited 1×
“org via an antiproliferation effect (243, 244) contributing to improved survival (245).”
BackgroundThe metabolism and bioavailability of morphine in patients with severe liver cirrhosis.
Hasselstrom, J., Eriksson, S., Persson, A., Rane, A., Svensson, J., & Sawe, J. (1990) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1990.tb03638.x · Cited by 205 · cited 1×
“The half-life of morphine is approximately twice as long in cirrhotic patients as that in healthy controls (484, 485).”
BackgroundPatt, Y. Z., Hassan, M. M., Aguayo, A., Nooka, A. K., Lozano, R. D., Curley, S. A., Vauthey, J., Ellis, L. M., Schnirer, I. I., Wolff, R. A., et al. (2004) · Cancer · doi:10.1002/cncr.20368 · Cited by 203
Hepatitis B vaccines: WHO position paper—Recommendations
(2010) · Vaccine · doi:10.1016/j.vaccine.2009.10.110 · Cited by 202
Individual patient data analysis to assess modifications to the RECIST criteria
Bogaerts, J., Ford, R., Sargent, D., Schwartz, L. H., Rubinstein, L., Lacombe, D., Eisenhauer, E., Verweij, J., & Therasse, P. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.027 · Cited by 202 · cited 1×
“In these criteria, overall responses are determined after evaluating the treatment responses for all lesions that are targeted or nontargeted (492, 493).”
BackgroundJang, J. W., Choi, J. Y., Bae, S. H., Yoon, S. K., Chang, I. U., Kim, C. W., Cho, S. H., Han, J. Y., & Lee, Y. S. (2006) · Hepatology · doi:10.1002/hep.21024 · Cited by 198 · cited 11×
“Downstaging of HCC with TACE may be possible in 24–63% of cases (178, 196, 202, 203).”
BackgroundInfluentialHung, I. F. N., Poon, R. T. P., Lai, C.-L., Fung, J., Fan, S.-T., & Yuen, M.-F. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2008.01872.x · Cited by 197
Cleary, J., Gelband, H., & Wagner, J. (2015) · Disease Control Priorities, Third Edition (Volume 3): Cancer · doi:10.1596/978-1-4648-0349-9_ch9 · Cited by 196
Louafi, S., Boige, V., Ducreux, M., Bonyhay, L., Mansourbakht, T., de Baere, T., Asnacios, A., Hannoun, L., Poynard, T., & Taïeb, J. (2007) · Cancer · doi:10.1002/cncr.22532 · Cited by 195 · cited 1×
“, in combination with gemcitabine (412) or capecitabine (413)) for HCC have been reported, but the benefits of these regimens compared to monotherapy are still lacking.”
BackgroundYin, Z., Fan, X., Ye, H., Yin, D., & Wang, J. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2705-8 · Cited by 195 · cited 1×
“Many studies show that the efficacy and safety of laparoscopic hepatic resection is comparable to those of open hepatic resection for small HCCs located in the left lateral section or on the surface of the right liver (122).”
ResultSong, I., Rhim, H., Lim, H. K., Kim, Y., & Choi, D. (2009) · European Radiology · doi:10.1007/s00330-009-1463-x · Cited by 195 · cited 1×
“However, the risk of thermal injury to the adjacent abdominal organs can be overcome by inducing artificial ascites (256).”
BackgroundPhase I study of sorafenib in Japanese patients with hepatocellular carcinoma
Furuse, J., Ishii, H., Nakachi, K., Suzuki, E., Shimizu, S., & Nakajima, K. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2007.00648.x · Cited by 194 · cited 1×
“In clinical practice, the safety and efficacy of sorafenib are reported to be comparable between Child-Pugh class A and B patients (379-382); however, the prognosis is reported to differ with respect to the presence of ascites and Child-Pugh score (383).”
BackgroundLok, A. S., Everhart, J. E., Wright, E. C., Di Bisceglie, A. M., Kim, H., Sterling, R. K., Everson, G. T., Lindsay, K. L., Lee, W. M., Bonkovsky, H. L., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.11.050 · Cited by 192 · cited 2×
“Previous studies including Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) (30, 31) and Evaluation of PegIntron in Control of Hepatitis C Cirrhosis (EPIC) studies (32) show that maintenance therapy with pegylated-interferon in cirrhotic patients does not significantly decrease the incidence of HCC…”
BackgroundLive Donors in Liver Transplantation
Brown, R. S. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.02.092 · Cited by 192
Lau, G. K. K., He, M., Fong, D., Bartholomeusz, A., Au, W., Lie, A. K. W., LOCARNINI, S. A., & Liang, R. H. S. (2002) · Hepatology · doi:10.1053/jhep.2002.35068 · Cited by 192 · cited 1×
“, breast cancer, hematologic malignancies, and other solid cancers) (430, 432-435).”
BackgroundA Novel Model Measuring the Harm of Transplanting Hepatocellular Carcinoma Exceeding Milan Criteria
Volk, M. L., Vijan, S., & Marrero, J. A. (2008) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2007.02138.x · Cited by 189 · cited 1×
“Some studies chose a 5-year survival rate cutoff of 70%, because it is similar to the rate expected for patients undergoing LT for noncancerous conditions and liver grafts from deceased donors (180-182).”
BackgroundRossi, S., Ravetta, V., Rosa, L., Ghittoni, G., Viera, F. T., Garbagnati, F., Silini, E. M., Dionigi, P., Calliada, F., Quaretti, P., et al. (2011) · Hepatology · doi:10.1002/hep.23965 · Cited by 185 · cited 1×
“Thus, early detection of local recurrence after RFA is of the utmost importance (515).”
BackgroundYuen, M.-F., Poon, R. T.-P., Lai, C.-L., Fan, S.-T., Lo, C.-M., Wong, K.-W., Wong, W. M., & Wong, B. C.-Y. (2002) · Hepatology · doi:10.1053/jhep.2002.35071 · Cited by 184 · cited 1×
“In addition, octreotide (402, 403), interferon (404), and tamoxifen (405)”
BackgroundLocal recurrence of hepatocellular carcinoma after percutaneous ethanol injection
Ishii, H., Okada, S., Nose, H., Okusaka, T., Yoshimori, M., Takayama, T., Kosuge, T., Yamasaki, S., Sakamoto, M., & Hirohashi, S. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960501)77:9<1792::aid-cncr6>3.0.co;2-e · Cited by 184 · cited 1×
“Local tumor progression rates after PEIT range between 24% and 34%, although there is no consensus on the definition of local tumor progression (275-277).”
BackgroundToso, C., Meeberg, G. A., Bigam, D. L., Oberholzer, J., Shapiro, A. M. J., Gutfreund, K., Ma, M. M., Mason, A. L., Wong, W. W. S., Bain, V. G., et al. (2007) · Transplantation · doi:10.1097/01.tp.0000262607.95372.e0 · Cited by 181 · cited 1×
“org via an antiproliferation effect (243, 244) contributing to improved survival (245).”
BackgroundYamada, K., Izaki, K., Sugimoto, K., Mayahara, H., Morita, Y., Yoden, E., Matsumoto, S., Soejima, T., & Sugimura, K. (2003) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(03)00434-6 · Cited by 178 · cited 1×
“An advantage of EBRT is that it can be performed safely regardless of the presence of portal vein invasion by the tumor (330-344).”
BackgroundHepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy
Yeo, W., Lam, K. C., Zee, B., Chan, P. S. K., Mo, F. K. F., Ho, W. M., Wong, W. L., Leung, T. W. T., Chan, A. T. C., Ma, B., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh430 · Cited by 177 · cited 3×
“, breast cancer, hematologic malignancies, and other solid cancers) (430, 432-435).”
BackgroundTaketomi, A., Sanefuji, K., Soejima, Y., Yoshizumi, T., Uhciyama, H., Ikegami, T., Harada, N., Yamashita, Y., Sugimachi, K., Kayashima, H., et al. (2009) · Transplantation · doi:10.1097/tp.0b013e3181943bee · Cited by 176 · cited 1×
“7% was achieved in patients with HCCs ≤ 5 cm and serum PIVKA-II levels < 300 mAU/mL (218).”
BackgroundWong, J. S.-W., Wong, G. L.-H., Tsoi, K. K.-F., Wong, V. W.-S., Cheung, S. Y.-S., Chong, C.-N., Wong, J., Lee, K.-F., Lai, P. B.-S., & Chan, H. L.-Y. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04634.x · Cited by 176 · cited 1×
“A meta-analysis including 551 patients from nine cohorts (35) shows a significant difference in the incidence of HCC recurrence in favor of the antiviral treatment group (55% vs.”
MethodPathology of Early Hepatocellular Carcinoma: Conventional and Molecular Diagnosis
Roskams, T., & Kojiro, M. (2010) · Seminars in Liver Disease · doi:10.1055/s-0030-1247129 · Cited by 175 · cited 1×
“The diagnostic sensitivity of fine-needle aspiration cytology, fine-needle aspiration biopsy, and core needle biopsy are reported to be 67% to 93% but much lower in patients with small HCC < 2 cm or targeting problems (63, 64).”
BackgroundLesurtel, M., Müllhaupt, B., Pestalozzi, B. C., Pfammatter, T., & Clavien, P.-A. (2006) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2006.01509.x · Cited by 175 · cited 1×
“Many studies report survival rates similar to those of untreated individuals (191-194); however, the major limitation of these studies is shorter waiting times (< 6 months) for LT (191, 192).”
ResultKornberg, A., Freesmeyer, M. G., Bärthel, E., Jandt, K., Katenkamp, K., Steenbeck, J., Sappler, A., Habrecht, O., Gottschild, D., & Settmacher, U. (2009) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2008.02516.x · Cited by 174 · cited 1×
“, high cellular dedifferentiation and microvascular invasion), resulting in worse recurrence-free survival after LT (169, 170).”
BackgroundCescon, M., Colecchia, A., Cucchetti, A., Peri, E., Montrone, L., Ercolani, G., Festi, D., & Pinna, A. D. (2012) · Annals of Surgery · doi:10.1097/sla.0b013e3182724ce8 · Cited by 173 · cited 1×
“Among them, transient elastography was recently reported to be effective for predicting postoperative hepatic failure (103-105).”
BackgroundLiving donor liver transplantation for hepatocellular carcinoma
Kulik, L., & Abecassis, M. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.042 · Cited by 171
Clinical results and risk factors of proton and carbon ion therapy for hepatocellular carcinoma
Komatsu, S., Fukumoto, T., Demizu, Y., Miyawaki, D., Terashima, K., Sasaki, R., Hori, Y., Hishikawa, Y., Ku, Y., & Murakami, M. (2011) · Cancer · doi:10.1002/cncr.26134 · Cited by 167 · cited 1×
“Proton therapy for HCC results in a 2-year local control rate from 75% to 96% and a 5-year survival rate from 23% to 44% (199, 326-329).”
BackgroundLiang, W., Wang, D., Ling, X., Allen Kao, A., Kong, Y., Shang, Y., Guo, Z., & He, X. (2012) · Liver Transplantation · doi:10.1002/lt.22441 · Cited by 164 · cited 1×
“org via an antiproliferation effect (243, 244) contributing to improved survival (245).”
BackgroundKhan, K. N., Yatsuhashi, H., Yamasaki, K., Yamasaki, M., Inoue, O., Koga, M., & Yano, M. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80072-0 · Cited by 162 · cited 1×
“Incomplete tumor necrosis often occurs after PEIT, and the local recurrence rate is up to 43% for large tumors > 3 cm (514).”
BackgroundPark, J.-W., Koh, Y. H., Kim, H. B., Kim, H. Y., An, S., Choi, J.-I., Woo, S. M., & Nam, B.-H. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.01.006 · Cited by 161 · cited 1×
“sorafenib in intermediate-stage HCC, a single-center phase II study shows longer survival and time to progression in combination therapy than a historic control group treated with TACE monotherapy (388); while another phase II study, the SPACE trial, does not show the beneficial outcomes of combination therapy (389);…”
ResultThe surgical approach to HCC: Our progress and results in Japan
Makuuchi, M., & Sano, K. (2004) · Liver Transplantation · doi:10.1002/lt.20044 · Cited by 157 · cited 1×
“Therefore, the indocyanine green 15-minute retention rate (ICG-R15), which was suggested in Japan, is evaluated at many Korean institutions as a preoperative test for the prediction of residual liver function (94).”
BackgroundKASL Clinical Practice Guidelines: Management of chronic hepatitis B
(2012) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2012.18.2.109 · Cited by 155
Kulik, L. M., Fisher, R. A., Rodrigo, D. R., Brown, R. S., Freise, C. E., Shaked, A., Everhart, J. E., Everson, G. T., Hong, J. C., Hayashi, P. H., et al. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2012.04272.x · Cited by 153 · cited 1×
“The higher recurrence observed after LDLT is likely due to differences in tumor characteristics, pretransplant HCC management, and waiting time (209-211).”
BackgroundYang, S. H., Suh, K., Lee, H. W., Cho, E., Cho, J. Y., Cho, Y. B., Yi, N., & Lee, K. U. (2006) · Liver Transplantation · doi:10.1002/lt.20861 · Cited by 152
Portal Hypertension: Contraindication to Liver Surgery?
Capussotti, L., Ferrero, A., Viganò, L., Muratore, A., Polastri, R., & Bouzari, H. (2006) · World Journal of Surgery · doi:10.1007/s00268-005-0524-9 · Cited by 150
Xi, M., Zhang, L., Zhao, L., Li, Q.-Q., Guo, S.-P., Feng, Z., Deng, X.-W., Huang, X.-Y., & Liu, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063864 · Cited by 149 · cited 1×
“An advantage of EBRT is that it can be performed safely regardless of the presence of portal vein invasion by the tumor (330-344).”
BackgroundManagement of Sorafenib-Related Adverse Events: A Clinician’s Perspective
Brose, M. S., Frenette, C. T., O’Keefe, S. J., & Stein, S. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.01.001 · Cited by 147 · cited 1×
“Furthermore, it is recommended to remove thick calluses, wear comfortable shoes with cushioning, avoid hot water, and take analgesics if necessary (384).”
BackgroundPelletier, S. J., Fu, S., Hoffman, V., Romero‐Marrero, C., Batheja, M. J., Punch, J. D., Magee, J. C., Lok, A. S.-F., Fontana, R. J., & Marrero, J. A. (2009) · Liver Transplantation · doi:10.1002/lt.21778 · Cited by 146
de Luna, W., Sze, D. Y., Ahmed, A., Ha, B., Ayoub, W. S., Keeffe, E. B., Cooper, A. D., Esquivel, C. O., & Nguyen, M. H. (2009) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.02576.x · Cited by 146 · cited 2×
“suggests that HCC candidates should be prioritized with respect to their response to bridging therapy (195) that improved overall survival after LT is expected (196).”
BackgroundDoes Therapeutic Use of Acetaminophen Cause Acute Liver Failure?
Dart, R. C., & Bailey, E. (2007) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.27.9.1219 · Cited by 145 · cited 1×
“Although one case report demonstrates that even therapeutic doses of acetaminophen less than 4 g/day in alcoholic patients without liver cirrhosis can result in acute liver failure (468), other studies show 4 g/day in alcoholic patients is not associated with a significant increase in liver toxicity (469, 470).”
ResultUeno, S., Tanabe, G., Nuruki, K., Hamanoue, M., Komorizono, Y., Oketani, M., Hokotate, H., Inoue, H., Baba, Y., Imamura, Y., et al. (2002) · Hepatology Research · doi:10.1016/s1386-6346(02)00144-4 · Cited by 144 · cited 5×
“The KLCSG and The Korea NCC have adopted the fifth version of the mUICC staging system as a primary staging system for HCC in 2003 (Table 4) (80).”
BackgroundMethodInfluentialMeng, M., Cui, Y., Lü, Y., She, B., Chen, Y., Guan, Y., & Zhang, R. (2008) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2008.11.002 · Cited by 143 · cited 1×
“that the use of TACE in combination with EBRT improves the 3-year survival rate by 10–28% compared to TACE monotherapy (346).”
BackgroundAnatomic versus limited nonanatomic resection for solitary hepatocellular carcinoma
Tanaka, K., Shimada, H., Matsumoto, C., Matsuo, K., Nagano, Y., Endo, I., & Togo, S. (2008) · Surgery · doi:10.1016/j.surg.2008.01.006 · Cited by 138 · cited 1×
“Although some reports suggest anatomical resection may be superior to nonanatomical resection by securing the resection margin and removing micro-metastases (116), further confirmation is required, because the results are inconsistent (117).”
ResultPorrett, P. M., Peterman, H., Rosen, M. A., Sonnad, S. S., Soulen, M. C., Markmann, J. F., Shaked, A. A., Furth, E. E., Reddy, K. R., & Olthoff, K. M. (2006) · Liver Transplantation · doi:10.1002/lt.20636 · Cited by 137 · cited 1×
“Many studies report survival rates similar to those of untreated individuals (191-194); however, the major limitation of these studies is shorter waiting times (< 6 months) for LT (191, 192).”
ResultHe, J., Zeng, Z., Tang, Z., Fan, J., Zhou, J., Zeng, M., Wang, J., Sun, J., Chen, B., Yang, P., et al. (2009) · Cancer · doi:10.1002/cncr.24300 · Cited by 136 · cited 1×
“In HCC patients with symptomatic bone metastases, EBRT is reported to relieve pain in 75–99% of patients (366-370) as well as symptoms in patients with brain metastases from HCC (371).”
BackgroundHepatitis B Virus Reactivation After Cytotoxic Chemotherapy: The Disease and Its Prevention
Mindikoglu, A. L., Regev, A., & Schiff, E. R. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.05.027 · Cited by 136 · cited 1×
“, breast cancer, hematologic malignancies, and other solid cancers) (430, 432-435).”
BackgroundWong, G. L., Chan, H. L., Tse, Y., Chan, H., Tse, C., Lo, A. O., & Wong, V. W. (2013) · Hepatology · doi:10.1002/hep.26739 · Cited by 135 · cited 1×
“If serum AFP level increases steadily over time, especially in hepatitis B patients with fully suppressed viral activity, the development of HCC should be suspected, and a detailed imaging study is strongly recommended (45, 48, 49).”
BackgroundRandomized Controlled Trial of Tamoxifen in Advanced Hepatocellular Carcinoma
Barbare, J., Bouché, O., Bonnetain, F., Raoul, J., Rougier, P. R., Abergel, A., Boige, V., Denis, B., Blanchi, A., Pariente, A. E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.470 · Cited by 134 · cited 1×
“In addition, octreotide (402, 403), interferon (404), and tamoxifen (405)”
BackgroundYang, H., Lee, J., Lee, D. H., Yu, S. J., Kim, Y. J., Yoon, J., Kim, H., Lee, J. M., Chung, J. W., Yi, N., et al. (2014) · Radiology · doi:10.1148/radiol.13131760 · Cited by 134 · cited 1×
“, the differences in the survival outcomes among the groups lost statistical significance (299).”
BackgroundKim, B. K., Park, J. Y., Kim, D. Y., Kim, J. K., Kim, K. S., Choi, J. S., Moon, B. S., Han, K., Chon, C. Y., Moon, Y. M., et al. (2007) · Liver International · doi:10.1111/j.1478-3231.2007.01625.x · Cited by 131
Chen, L.-T., Chen, M.-F., Li, L.-A., Lee, P.-H., Jeng, L.-B., Lin, D.-Y., Wu, C.-C., Mok, K.-T., Chen, C.-L., Lee, W.-C., et al. (2012) · Annals of Surgery · doi:10.1097/sla.0b013e3182363ff9 · Cited by 129
Tanaka, H., Hirohashi, K., Kubo, S., Shuto, T., Higaki, I., & Kinoshita, H. (2000) · British journal of surgery · doi:10.1046/j.1365-2168.2000.01438.x · Cited by 129 · cited 1×
“org Some reports assert that portal vein embolization before extensive hepatic resection might induce compensatory hypertrophy of the residual liver and reduce the risk of surgery, especially in cases with liver cirrhosis; nonetheless, these are largely debatable (112, 113).”
BackgroundLiang, H.-H., Chen, M.-S., Peng, Z., Zhang, Y., Zhang, Y.-Q., Li, J. Q., & Lau, W. Y. (2008) · Annals of Surgical Oncology · doi:10.1245/s10434-008-0076-y · Cited by 129 · cited 1×
“Another retrospective study shows similar results (272).”
Chan, A. C. Y., Chan, S. C., Chok, K., Cheung, T. T., Chiu, D. W., Poon, R. T. P., Fan, S. T., & Lo, C. M. (2013) · Liver Transplantation · doi:10.1002/lt.23605 · Cited by 127
Liu, L., Wang, Z., Jiang, S., Shao, B., Liu, J., Zhang, S., Zhou, Y., Zhou, Y., & Zhang, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064261 · Cited by 127 · cited 1×
“A recent meta-analysis reports that intraoperative transfusion increases complication rates and reduces overall and disease-free survival rates after resection in HCC patients (114).”
BackgroundRadiotherapy for painful bone metastases from hepatocellular carcinoma
Seong, J., Koom, W. S., & Park, H. C. (2005) · Liver International · doi:10.1111/j.1478-3231.2005.01094.x · Cited by 126 · cited 1×
“In HCC patients with symptomatic bone metastases, EBRT is reported to relieve pain in 75–99% of patients (366-370) as well as symptoms in patients with brain metastases from HCC (371).”
BackgroundSalvage living donor liver transplantation after prior liver resection for hepatocellular carcinoma
Hwang, S., Lee, S., Moon, D., Ahn, C., Kim, K., Lee, Y. J., Ha, T., & Song, G. (2007) · Liver Transplantation · doi:10.1002/lt.21157 · Cited by 125 · cited 2×
“The indications and selection criteria for salvage LDLT are same as those for primary LDLT (153, 236-239).”
BackgroundLu, Z., Wen, F., Guo, Q., Liang, H., Mao, X., & Sun, H. (2012) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e32835a0a07 · Cited by 125 · cited 1×
“Meta-analyses of RCTs also show similar results (269, 270).”
ResultBrain metastases from hepatocellular carcinoma: prognostic factors and outcome
Choi, H. J., Cho, B. C., Sohn, J., Shin, S. J., Kim, S. H., Kim, J. H., & Yoo, N. C. (2008) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9713-3 · Cited by 125 · cited 1×
“In HCC patients with symptomatic bone metastases, EBRT is reported to relieve pain in 75–99% of patients (366-370) as well as symptoms in patients with brain metastases from HCC (371).”
BackgroundHuang, G., Lai, E. C. H., Lau, W. Y., Zhou, W., Shen, F., Pan, Z., Fu, S., & Wu, M. (2012) · Annals of Surgery · doi:10.1097/sla.0b013e318262b218 · Cited by 123 · cited 1×
“In cases in which antiviral therapy is expected to continue for more than 12 months in particular, the antiviral drug with the minimum resistance profile should be selected (439, 440).”
BackgroundThe Therapeutic Use of Acetaminophen in Patients with Liver Disease
Benson, G. D., Koff, R. S., & Tolman, K. G. (2005) · American Journal of Therapeutics · doi:10.1097/01.mjt.0000140216.40700.95 · Cited by 122 · cited 1×
“drug metabolism and increased half-life (475, 476).”
Lang, H., Sotiropoulos, G. C., Dömland, M., Frühauf, N. R., Paul, A., Hüsing, J., Malagó, M., & Broelsch, C. E. (2005) · Journal of British Surgery · doi:10.1002/bjs.4763 · Cited by 121 · cited 1×
“Hepatic resection is not only a primary treatment option for HCC unaccompanied by liver cirrhosis (84), but should also be preferentially considered even for HCC with cirrhosis if the liver function is expected to be able to tolerate surgery (85, 86).”
BackgroundSelection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma
Minagawa, M., Takayama, T., Kokudo, N., & Makuuchi, M. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)83515-1 · Cited by 121
Kim, J., Kim, S. H., Lee, S. J., & Rhim, H. (2011) · American Journal of Roentgenology · doi:10.2214/ajr.10.4394 · Cited by 118 · cited 3×
“Diagnosis should be based on the combination of the identification of the typical hallmark of HCC in two or more imaging modalities and increased serum AFP with an increasing trend over time for liver nodules < 1 cm in patients with suppressed hepatitis activity (57).”
BackgroundMethodResultHuang, Z., Liang, B.-Y., Xiong, M., Zhan, D., Wei, S., Wang, G., Chen, Y.-F., & Chen, X. (2012) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2269-7 · Cited by 118 · cited 1×
“The 5-year survival rate of patients who undergo reresection of intrahepatic recurrence after initial surgery ranges from 37% to 70% (140, 150-152).”
BackgroundProton-Beam Therapy for Hepatocellular Carcinoma Associated with Portal Vein Tumor Thrombosis*
Sugahara, S., Nakayama, H., Fukuda, K., Mizumoto, M., Tokita, M., Abei, M., Shoda, J., Matsuzaki, Y., Thono, E., Tsuboi, K., et al. (2009) · Strahlentherapie und Onkologie · doi:10.1007/s00066-009-2020-x · Cited by 117 · cited 1×
“An advantage of EBRT is that it can be performed safely regardless of the presence of portal vein invasion by the tumor (330-344).”
BackgroundCucchetti, A., Cescon, M., Bigonzi, E., Piscaglia, F., Golfieri, R., Ercolani, G., Morelli, M. C., Ravaioli, M., & Pinna, A. D. (2011) · Liver Transplantation · doi:10.1002/lt.22397 · Cited by 116
Liver Stiffness Measurement by Transient Elastography as a Predictor on Posthepatectomy Outcomes
Wong, J. S.-W., Wong, G. L.-H., Chan, A. W.-H., Wong, V. W.-S., Cheung, Y.-S., Chong, C.-N., Wong, J., Lee, K.-F., Chan, H. L.-Y., & Lai, P. B.-S. (2013) · Annals of Surgery · doi:10.1097/sla.0b013e318269d2ec · Cited by 115
Treatment for Hepatocellular Carcinoma in Elderly Patients: A Literature Review
Nishikawa, H., Kimura, T., Kita, R., & Osaki, Y. (2013) · Journal of Cancer · doi:10.7150/jca.7279 · Cited by 113 · cited 1×
“Nevertheless, major hepatic resection should be considered with caution, because hepatic regeneration power gradually decreases with age (128-130).”
BackgroundThree-Quarters of Right Liver Donors Experienced Postoperative Complications† ‡
Yi, N., Suh, K., Cho, J. Y., Lee, H. W., Cho, E., Yang, S. H., Cho, Y. B., & Lee, K. U. (2007) · Liver Transplantation · doi:10.1002/lt.21030 · Cited by 113 · cited 1×
“The outcomes of live donors (n = 2872 published cases) from Korea are excellent (223-228).”
BackgroundPIVKA-II Is a Useful Tumor Marker for Recurrent Hepatocellular Carcinoma after Surgical Resection
Kim, D. Y., Paik, Y. H., Ahn, S. H., Youn, Y. J., Choi, J. W., Kim, J. K., Lee, K. S., Chon, C. Y., & Han, K. (2007) · Oncology · doi:10.1159/000111707 · Cited by 113 · cited 1×
“PIVKA-II is another HCC marker with increasing utility for diagnosis, follow-up, and prognostication of HCC (147, 149).”
BackgroundAndreou, A., Vauthey, J., Cherqui, D., Zimmitti, G., Ribero, D., Truty, M. J., Wei, S. H., Curley, S. A., Laurent, A., Poon, R. T. P., et al. (2012) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-012-2005-4 · Cited by 112
Koo, J. E., Kim, J. H., Lim, Y., Park, S. J., Won, H. J., Sung, K., & Suh, D. J. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.07.1730 · Cited by 111 · cited 1×
“7 months in comparison with the historical cohort who received TACE alone (350).”
ResultLee, H.-S., Kim, K. M., Yoon, J., Lee, T. R., Suh, K., Lee, K. U., Chung, J. W., Park, J. H., & Kim, C. Y. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.02.013 · Cited by 111 · cited 1×
“In addition, the survival rate of the TACE group in stage T1 and T2 cases was similar to that of the surgical resection group if iodized oil was compactly retained within the tumor (297).”
ResultModel to estimate survival in ambulatory patients with hepatocellular carcinoma
Yang, J. D., Kim, W. R., Park, K. W., Chaiteerakij, R., Kim, B., Sanderson, S. O., Larson, J. J., Pedersen, R. A., Therneau, T. M., Gores, G. J., et al. (2012) · Hepatology · doi:10.1002/hep.25680 · Cited by 110 · cited 1×
“In addition, the monitoring interval should be individualized on the basis of patient-specific risk factors according to tumor biology and underlying liver diseases (516, 517).”
BackgroundBruix, J., Poynard, T., Colombo, M., Schiff, E., Burak, K., Heathcote, E. J. L., Berg, T., Poo, J., Mello, C. B., Guenther, R., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.03.010 · Cited by 106 · cited 1×
“Previous studies including Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) (30, 31) and Evaluation of PegIntron in Control of Hepatitis C Cirrhosis (EPIC) studies (32) show that maintenance therapy with pegylated-interferon in cirrhotic patients does not significantly decrease the incidence of HCC…”
BackgroundBoucher, É., Corbinais, S., Rolland, Y., Bourguet, P., Guyader, D., Boudjéma, K., Meunier, B., & Raoul, J. (2003) · Hepatology · doi:10.1053/jhep.2003.50473 · Cited by 106 · cited 1×
“Although one study reports that (131)I infusion via the hepatic artery after curative resection reduces the recurrence of HCC, no validation study was performed (426, 427).”
BackgroundKaizu, T., Karasawa, K., Tanaka, Y., Matuda, T., Kurosaki, H., Tanaka, S., & Kumazaki, T. (1998) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1998.00614.x · Cited by 106
Finkelstein, S. D., Marsh, W. J., Demetris, A. J., Swalsky, P. A., Sasatomi, E., Bonham, C. A., Subotin, M., & Dvorchik, I. (2003) · Hepatology · doi:10.1053/jhep.2003.50134 · Cited by 105 · cited 1×
“The two recurrence entities can be differentiated by means of genomic hybridization, deoxyribonucleic acid (DNA) fingerprinting, DNA microarray, or HBV integration pattern (141).”
BackgroundHo, C., Lee, P., Shau, W., Ho, M., Wu, Y., & Hu, R. (2012) · Surgery · doi:10.1016/j.surg.2011.12.015 · Cited by 103 · cited 1×
“83%, respectively; the differences are not statistically significant (271).”
BackgroundResection of Hepatocellular Carcinoma with Macroscopic Vascular Invasion
Roayaie, S., Jibara, G. A., Taouli, B. A., & Schwartz, M. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-013-3074-7 · Cited by 102 · cited 1×
“Nevertheless, surgical resection would be at least more effective than medical treatment (136).”
BackgroundUeshima, K., Kudo, M., Takita, M., Nagai, T., Tatsumi, C., 上田, 泰., Kitai, S., Ishikawa, E., Yada, N., Inoue, T., et al. (2010) · Oncology · doi:10.1159/000315244 · Cited by 102
Zeng, Z., Tang, Z., Fan, J., Qin, L., Ye, S.-L., Zhou, J., Sun, H., Wang, B., & Wang, J. (2005) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2005.03.058 · Cited by 101 · cited 1×
“In HCC patients with abdominal lymph node metastases, EBRT results in response rates of approximately 80% (361-364) with improved median survival time (365).”
BackgroundKim, J. H., Park, J., Kim, T. H., Koh, D. W., Lee, W. J., & Kim, C.-M. (2007) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.04.005 · Cited by 101
Pharmacokinetics and ventilatory effects of oxycodone before and after liver transplantation*
Tallgren, M. K., Olkkola, K. T., Seppαlä, T., Höckerstedt, K. A. V., & Lindgren, L. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90100-4 · Cited by 99 · cited 1×
“The elimination half-life of oxycodone is prolonged, while its clearance is diminished with significant ventilation depression in pretransplantation liver cirrhosis patients compared to posttransplantation patients (488).”
BackgroundLao, X., Luo, G., Ye, L., Luo, C., Shi, M., Wang, D., Guo, R., Chen, M., Li, S., Lin, X., et al. (2013) · Liver International · doi:10.1111/liv.12112 · Cited by 98 · cited 1×
“Comparatively many studies have evaluated HBV reactivation during TACE for the treatment of HCC; HBV reactivation is reported to occur in 4–40% of patients (430, 441-445).”
BackgroundKudo, M., Hatanaka, K., & Maekawa, K. (2010) · Oncology · doi:10.1159/000315229 · Cited by 97 · cited 1×
“However, recent applications of ultrasound contrast agents and fusion imaging techniques have broadened the indications for RFA to such cases (257, 258).”
BackgroundGrant, R. C., Sandhu, L., Dixon, P. R., Greig, P. D., Grant, D. R., & McGilvray, I. D. (2012) · Clinical Transplantation · doi:10.1111/ctr.12031 · Cited by 95 · cited 2×
“Furthermore, future studies must have better study design and reporting in order to accurately describe the observed difference in disease-free survival due to inappropriate study design or biological risk specifically associated with LDLT (208).”
BackgroundKim, S. U., Ahn, S. H., Park, J. Y., Kim, D. Y., Chon, C. Y., Choi, J. S., Kim, K. S., & Han, K. (2008) · Hepatology International · doi:10.1007/s12072-008-9091-0 · Cited by 92 · cited 1×
“Among them, transient elastography was recently reported to be effective for predicting postoperative hepatic failure (103-105).”
Background(FFCD), O. B. O. T. F. F. D. C. D., Boige, V., Raoul, J., Pignon, J., Bouché, O., Blanc, J.-F., Dahan, L., Jouve, J.-L., Dupouy, N., & Ducreux, M. P. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603956 · Cited by 91 · cited 1×
“, in combination with gemcitabine (412) or capecitabine (413)) for HCC have been reported, but the benefits of these regimens compared to monotherapy are still lacking.”
BackgroundCheng, A., Amarapurkar, D. N., Chao, Y., Chen, P., Geschwind, J.-F. H., Goh, K., Han, K., Kudo, M., Lee, H. C., Lee, R., et al. (2013) · Liver International · doi:10.1111/liv.12314 · Cited by 89 · cited 1×
“, 3 times within 6 months) for residual or recurrent tumors after the initial TACE, sorafenib might be indicated on the basis of the concept of TACE failure or refractoriness (385-387).”
BackgroundQi, X., Tang, Y., An, D., Bai, M., Shi, X., Wang, J., Han, G., & Fan, D. (2013) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000008 · Cited by 87 · cited 1×
“Nevertheless, it is not possible to draw a definite conclusion about the overall or disease-free survival rate of HCC patients on the basis of a meta-analysis of the three RCTs mentioned above, because the indications differed substantially among studies (265).”
BackgroundLee, M. W., Rhim, H., Cha, D. I., Kim, Y. J., & Lim, H. K. (2013) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2013.04.007 · Cited by 87 · cited 1×
“However, recent applications of ultrasound contrast agents and fusion imaging techniques have broadened the indications for RFA to such cases (257, 258).”
BackgroundIbuprofen-Induced Hepatotoxicity in Patients With Chronic Hepatitis C: A Case Series
Riley, T., & Smith, J. P. (1998) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1998.00484.x · Cited by 87 · cited 1×
“Indeed, roughly 10% of total drug-induced hepatotoxicity cases are related to NSAIDs (478), and NSAID-induced liver injury is well documents (466, 479).”
BackgroundSorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function
Kim, J. E., Ryoo, B., Ryu, M., Chang, H.-M., Suh, D. J., Lee, H. C., Lim, Y., Kim, K. M., & Kang, Y. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1616-x · Cited by 85 · cited 1×
“In clinical practice, the safety and efficacy of sorafenib are reported to be comparable between Child-Pugh class A and B patients (379-382); however, the prognosis is reported to differ with respect to the presence of ascites and Child-Pugh score (383).”
BackgroundSymptom Clusters and Quality of Life in Korean Patients With Hepatocellular Carcinoma
Ryu, E., Kim, K., Cho, M. S., Kwon, I. G., Kim, H. S., & Fu, M. R. (2009) · Cancer Nursing · doi:10.1097/ncc.0b013e3181b4367e · Cited by 85
Choi, G. H., Kim, D. H., Kang, C. M., Kim, K. S., Choi, J., Lee, W. J., & Kim, B.-R. (2007) · Annals of Surgical Oncology · doi:10.1245/s10434-007-9671-6 · Cited by 83 · cited 1×
“The 5-year survival rate of patients who undergo reresection of intrahepatic recurrence after initial surgery ranges from 37% to 70% (140, 150-152).”
BackgroundPhase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma
Lee, J., Park, J. O., Kim, W. S., Park, S. H., Park, K. W., Choi, M. S., Lee, J. H., Koh, K. C., Paik, S. W., Yoo, B. C., et al. (2004) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-004-0837-7 · Cited by 83 · cited 1×
“, in combination with doxorubicin (408), capecitabine (409, 410), or 5-fluorouracil (411)) or oxaliplatin-containing regimens (e.”
BackgroundHCC in Living Donor Liver Transplantation: Can We Expand the Milan Criteria?
Kwon, C. H. D., Kim, D. J., Han, Y. S., Park, J. B., Choi, G., Kim, S. J., Joh, J., & Lee, S. (2007) · Digestive Diseases · doi:10.1159/000106911 · Cited by 81
Park, J., Amarapurkar, D. N., Chao, Y., Chen, P., Geschwind, J. H., Goh, K., Han, K., Kudo, M., Lee, H. C., Lee, R., et al. (2012) · Liver International · doi:10.1111/liv.12083 · Cited by 78 · cited 1×
“, 3 times within 6 months) for residual or recurrent tumors after the initial TACE, sorafenib might be indicated on the basis of the concept of TACE failure or refractoriness (385-387).”
BackgroundPark, M.-S., Lee, K., Suh, S., You, T. S., Choi, Y., Kim, H., Hong, G. S., Yi, N., Kwon, C. H. D., Joh, J., et al. (2013) · Transplantation · doi:10.1097/tp.0b013e3182a68953 · Cited by 77
Prajapati, H. J., Dhanasekaran, R., El‐Rayes, B. F., Kauh, J. S. W., Maithel, S. K., Chen, Z., & Kim, H. S. (2013) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2012.11.026 · Cited by 76
Kuffner, E., Green, J., Bogdan, G., Knox, P., Palmer, R., Heard, K., Slattery, J., & Dart, R. (2007) · BMC Medicine · doi:10.1186/1741-7015-5-13 · Cited by 75 · cited 1×
“Although one case report demonstrates that even therapeutic doses of acetaminophen less than 4 g/day in alcoholic patients without liver cirrhosis can result in acute liver failure (468), other studies show 4 g/day in alcoholic patients is not associated with a significant increase in liver toxicity (469, 470).”
ResultCucchetti, A., Vitale, A., Gaudio, M. D., Ravaioli, M., Ercolani, G., Cescon, M., Zanello, M., Morelli, M. C., Cillo, U., Grazi, G. L., et al. (2010) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.02984.x · Cited by 73
How should patients with hepatocellular carcinoma recurrence after liver transplantation be treated?
Schwartz, M., Roayaie, S., & Llovet, J. M. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2005.07.019 · Cited by 73 · cited 1×
“Posttransplantation Immunosuppression A calcineurine inhibitor-based immunosuppressant is generally administered in HCC patients after LT (242).”
BackgroundLiver transplantation for HCC: its role
Hwang, S., Lee, S., & Belghiti, J. (2009) · Journal of Hepato-Biliary-Pancreatic Sciences · doi:10.1007/s00534-009-0241-0 · Cited by 72 · cited 1×
“recipients with HCC has recently increased to 30–40% in Korea, suggesting LDLT is now one of the main treatment modalities for HCC (207).”
BackgroundMetronomic Capecitabine in Advanced Hepatocellular Carcinoma Patients: A Phase II Study
Brandi, G., Rosa, F. D., Agostini, V., Girolamo, S. D., Andreoné, P., Bolondi, L., Serra, C., Sama, C., Golfieri, R., Gramenzi, A., et al. (2013) · The Oncologist · doi:10.1634/theoncologist.2013-0093 · Cited by 72 · cited 1×
“Cytotoxic chemotherapy can be considered in cases of HCC progression on sorafenib or drug intolerance (390-392).”
BackgroundHEARD, K., GREEN, J. L., BAILEY, J. E., BOGDAN, G. M., & DART, R. C. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03368.x · Cited by 71 · cited 1×
“Moreover, one study shows a significant increase in the liver enzymes of alcoholic patients taking acetaminophen 4 g/day (471).”
BackgroundWhich matters most: Number of tumors, size of the largest tumor, or total tumor volume?
Germani, G., Gurusamy, K. S., Garcovich, M., Toso, C., Fede, G., Hemming, A. W., Suh, K., Weber, A., & Burroughs, A. K. (2011) · Liver Transplantation · doi:10.1002/lt.22336 · Cited by 71
Jang, J. W., Kwon, J. H., You, C. R., Kim, J.-D., Woo, H. Y., Bae, S. H., Choi, J. Y., Yoon, S. K., & Chung, K. W. (2011) · Antiviral Therapy · doi:10.3851/imp1840 · Cited by 69 · cited 2×
“Another recent report suggests concurrent TACE and external radiotherapy may double the HBV reactivation rate compared to TACE alone (446).”
BackgroundMiao, R. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i23.2931 · Cited by 68 · cited 2×
“(36), the estimated ORs for the 1-, 3-, and 5-year recurrence in HCV-related HCC were significantly reduced to 0.”
BackgroundDan, J., Zhang, Y., Huang, J., Chen, M.-S., Gao, H., Peng, Z., Xu, L., & Lau, W. Y. (2013) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2013.03.020 · Cited by 68
Toward optimizing the indications for orthotopic liver transplantation in hepatocellular carcinoma
Samuel, D., Colombo, M., El‐Serag, H. B., Sobesky, R., & Heaton, N. D. (2011) · Liver Transplantation · doi:10.1002/lt.22423 · Cited by 67
Cho, J., Paik, Y., Park, H. C., Yu, J. I., Sohn, W., Gwak, G., Choi, M. S., Lee, J. H., Koh, K. C., Paik, S. W., et al. (2013) · Liver International · doi:10.1111/liv.12445 · Cited by 67
Yamashita, T., Arai, K., Sunagozaka, H., Ueda, T., Terashima, T., Yamashita, T., Mizukoshi, E., Sakai, A., Nakamoto, Y., Honda, M., et al. (2011) · Oncology · doi:10.1159/000334439 · Cited by 67 · cited 1×
“HAIC can be administered in combination with systemic interferon (421, 422).”
BackgroundLee, J. O., Lee, K., Oh, D., Kim, J. H., Im, S.-A., Kim, T. Y., & Bang, Y. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp010 · Cited by 67 · cited 1×
“, in combination with doxorubicin (408), capecitabine (409, 410), or 5-fluorouracil (411)) or oxaliplatin-containing regimens (e.”
BackgroundUpton, A. C. (2003) · Health Physics · doi:10.1097/00004032-200307000-00005 · Cited by 65 · cited 1×
“The International Commission on Radiological Protection (ICRP) reports that the cancer risk after radiation exposure exhibits a linear-nonthreshold dose-response relationship (72, 73).”
BackgroundBarbare, J., Bouché, O., Bonnetain, F., Dahan, L., Lombard‐Bohas, C., Faroux, R., Raoul, J., Cattan, S., Lemoine, A., Blanc, J., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.02.018 · Cited by 64 · cited 1×
“In addition, octreotide (402, 403), interferon (404), and tamoxifen (405)”
BackgroundKatamura, Y., Aikata, H., Takaki, S., Azakami, T., Kawaoka, T., Waki, K., Hiramatsu, A., Kawakami, Y., Takahashi, S., Kenjo, M., et al. (2009) · Journal of Gastroenterology · doi:10.1007/s00535-009-0033-y · Cited by 64 · cited 1×
“An advantage of EBRT is that it can be performed safely regardless of the presence of portal vein invasion by the tumor (330-344).”
BackgroundBoige, V., Taïeb, J., Hebbar, M., Malka, D., de Baère, T., Hannoun, L., Magherini, E., Mignard, D., Poynard, T., & Ducreux, M. P. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2005.09.034 · Cited by 64 · cited 1×
“Satisfactory results have not been obtained with single agents such as 5-fluorouracil (396), gemcitabine (397, 398), oxaliplatin (399), capecitabine (400), and irinotecan (401).”
BackgroundUse of Over-the-Counter Analgesics in Patients with Chronic Liver Disease
Rossi, S., Assis, D. N., Awsare, M., Brunner, M. I., Skole, K. S., Rai, J., Andrel, J. A., Herrine, S. K., Reddy, K. R., & Navarro, V. J. (2008) · Drug Safety · doi:10.2165/00002018-200831030-00007 · Cited by 64 · cited 1×
“Acetaminophen is the most common cause of fulminant hepatic failure (465, 466), but clinically significant hepatic injury is very rare when the dosage is limited to 4 g/day (467).”
BackgroundYu, J. I., Park, H. C., Lim, D. H., Park, W., Yoo, B. C., Paik, S. W., Koh, K. C., & Lee, J. H. (2011) · Journal of Korean Medical Science · doi:10.3346/jkms.2011.26.8.1014 · Cited by 64 · cited 1×
“An advantage of EBRT is that it can be performed safely regardless of the presence of portal vein invasion by the tumor (330-344).”
BackgroundChan, D. L., Alzahrani, N. A., Morris, D. L., & Chua, T. C. (2013) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12399 · Cited by 61 · cited 3×
“In addition, salvage transplantation could result in an excellent diseasefree survival rate > 60% if the conditions of the patient and recurrent tumors are suitable for transplantation (153, 154).”
BackgroundResultBargellini, I., Florio, F., Golfieri, R., Grosso, M., Lauretti, D. L., & Cioni, R. (2013) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-013-0656-5 · Cited by 58 · cited 1×
“TACE is the most commonly used nonsurgical treatment modality for these patients; meanwhile, tumor necrosis can be achieved by the combined effects of antitumor chemotherapy and selective ischemia of tumor tissue (13, 282, 283).”
Choi, G. H., Park, J. Y., Hwang, H. K., Kim, D., Kang, C. M., Choi, J. S., Park, Y. N., Kim, D. Y., Ahn, S. H., Han, K., et al. (2011) · Liver International · doi:10.1111/j.1478-3231.2010.02436.x · Cited by 58 · cited 1×
“The posthepatectomy complication rate is high and the long-term prognosis is poor in patients with portal hypertension (96-98).”
BackgroundChen, X., Zhang, B., Yin, X., Ren, Z., Qiu, S., & Zhou, J. (2013) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-012-1343-7 · Cited by 57 · cited 1×
“Furthermore, there is no evidence that TACE prevents HCC recurrence after curative resection (425).”
BackgroundRadner, H., Ramiro, S., Buchbinder, R., Landewé, R., van der Heijde, D. M. F. M., & Aletaha, D. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008951.pub2 · Cited by 56 · cited 1×
“However, there is a paucity of studies on pain management for patients with HCC and liver disease (461).”
BackgroundHu, Z., Wang, W., Li, Z., Ye, S., & Zheng, S. (2012) · Liver Transplantation · doi:10.1002/lt.23521 · Cited by 56 · cited 2×
“Meta-analyses and systemic reviews (154, 234, 241) show that the recipient outcomes of SLT are similar to those of primary LT with respect to overall and disease-free survival.”
BackgroundResultThe challenges of liver transplantation for hepatocellular carcinoma on cirrhosis
Bhoori, S., Sposito, C., Germini, A., Coppa, J. C., & Mazzaferro, V. (2010) · Transplant International · doi:10.1111/j.1432-2277.2010.01111.x · Cited by 56 · cited 1×
“Downstaging is more effective in cases in which tumor size is < 7 cm or there are fewer than 3 tumors (203), but there is no clear upper limit for the eligibility of downstaging (204).”
BackgroundInvited Commentary: Studies of Workers Exposed to Low Doses of Radiation
Gilbert, E. S. (2001) · American Journal of Epidemiology · doi:10.1093/aje/153.4.319 · Cited by 54 · cited 1×
“The International Commission on Radiological Protection (ICRP) reports that the cancer risk after radiation exposure exhibits a linear-nonthreshold dose-response relationship (72, 73).”
BackgroundKwak, H. A., Park, J., Nam, B., Yu, A., Woo, S. M., Kim, T. H., Kim, S. H., Koh, Y. H., Kim, H. B., Park, S., et al. (2013) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12470 · Cited by 53 · cited 5×
“TACE is the most commonly used nonsurgical treatment modality for these patients; meanwhile, tumor necrosis can be achieved by the combined effects of antitumor chemotherapy and selective ischemia of tumor tissue (13, 282, 283).”
BackgroundMethodInfluentialRadiation therapy for abdominal lymph node metastasis from hepatocellular carcinoma
Park, Y. J., Lim, D. H., Paik, S. W., Koh, K. C., Lee, J. H., Choi, M. S., Yoo, B. C., Nam, H. R., Oh, D. R., Park, W., et al. (2006) · Journal of Gastroenterology · doi:10.1007/s00535-006-1895-x · Cited by 52 · cited 1×
“In HCC patients with abdominal lymph node metastases, EBRT results in response rates of approximately 80% (361-364) with improved median survival time (365).”
BackgroundKhalid, S. K., Lane, J. A., Navarro, V. J., & García–Tsao, G. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.04.015 · Cited by 51 · cited 1×
“In patients with cirrhosis, acetaminophen 2–3 g/day is not associated with acute hepatic decompensation (472).”
BackgroundLiu, F., Wei, Y., Wang, W., Chen, K., Yan, L., Wen, T., Zhao, J., Xu, M., & Li, B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048932 · Cited by 51 · cited 1×
“The selection criteria for SLT are same as those for primary LT (153, 154, 232, 235-239).”
BackgroundKim, S., Na, G.-H., Choi, H.-J., Yoo, Y.-K., & Kim, D.-G. (2012) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-012-1865-y · Cited by 51 · cited 1×
“The outcomes of live donors (n = 2872 published cases) from Korea are excellent (223-228).”
BackgroundKim, B., Park, Y.-K., Kim, Y.-B., Wang, H.-J., & Kim, M.-W. (2008) · Transplantation Proceedings · doi:10.1016/j.transproceed.2008.03.175 · Cited by 48 · cited 2×
“The indications and selection criteria for salvage LDLT are same as those for primary LDLT (153, 236-239).”
BackgroundKim, D. Y., Park, B. J., Kim, Y. H., Han, K., Cho, S. B., Cho, K. R., Uhm, S.-H., Choe, J.-G., Choi, J. Y., Chun, H. J., et al. (2013) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e3182a78dba · Cited by 46 · cited 1×
“5% and the 3-year overall survival rate was 75% (314).”
BackgroundTerashima, T., Yamashita, T., Arai, K., Sunagozaka, H., Kitahara, M., Nakagawa, H., Kagaya, T., Mizukoshi, E., Honda, M., & Kaneko, S. (2013) · Hepatology Research · doi:10.1111/hepr.12266 · Cited by 43 · cited 1×
“Recent reports demonstrate that HAIC can also be tried for sorafenib-refractory or intolerant HCCs, although further studies are warranted (415, 416).”
BackgroundMoon, J. I., Kwon, C. H. D., Joh, J., Choi, G., Jung, G. O., Kim, J. M., Shin, M., Choi, S. J., Kim, S. J., & Lee, S. (2012) · Transplantation Proceedings · doi:10.1016/j.transproceed.2011.11.009 · Cited by 43 · cited 3×
“The indications and selection criteria for salvage LDLT are same as those for primary LDLT (153, 236-239).”
BackgroundSystemic Therapy for Hepatocellular Carcinoma
Thomas, M. B. (2008) · The Cancer Journal · doi:10.1097/ppo.0b013e31816a6058 · Cited by 43
Mir, O., Coriat, R., Boudou, P., Ropert, S., Durand, J.-P., Cessot, A., Mallet, V. O., Sogni, P., Chaussade, S., Pol, S., et al. (2012) · Medical Oncology · doi:10.1007/s12032-012-0208-x · Cited by 42 · cited 1×
“Cytotoxic chemotherapy can be considered in cases of HCC progression on sorafenib or drug intolerance (390-392).”
BackgroundThiele, M. S., Gluud, L. L., Dahl, E., & Krag, A. A. (2013) · BMJ Open · doi:10.1136/bmjopen-2013-003265 · Cited by 41 · cited 1×
“Although HCC reduction after antiviral treatment remains controversial (25), a recent study shows significant reduction in HCC incidence in patients treated with entecavir (5 years of follow-up; entecavir vs.”
BackgroundCha, D. I., Lee, M. W., Rhim, H., Choi, D., Kim, Y.-S., & Lim, H. K. (2013) · Korean Journal of Radiology · doi:10.3348/kjr.2013.14.2.240 · Cited by 41 · cited 1×
“However, the risk of biliary stricture is not eliminated by PEIT if the tumors are located in the liver hilum (274).”
BackgroundCortelezzi, A., Viganò, M., Zilioli, V. R., Fantini, N. N., Pasquini, M. C., DELILIERS, G., Colombo, M., & Lampertico, P. (2005) · Journal of Clinical Virology · doi:10.1016/j.jcv.2005.10.009 · Cited by 38 · cited 1×
“In cases of lamivudine resistance, antiviral drugs should be replaced according to the treatment guidelines for resistance (437, 438).”
BackgroundConformal chemoradiation for primary and metastatic liver malignancies
Dawson, L. A., McGinn, C. J., & Lawrence, T. S. (2003) · Seminars in Surgical Oncology · doi:10.1002/ssu.10043 · Cited by 36 · cited 1×
“External-beam radiation therapy is also effective for relieving symptoms such as cancer pain (315, 358).”
BackgroundSiegler, M. A., Simmerling, M. C., Siegler, J. H., & Cronin, D. C. (2006) · Liver Transplantation · doi:10.1002/lt.20670 · Cited by 33
Salvage liver transplantation in the treatment of hepatocellular carcinoma: A Meta-analysis
Li, H. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i19.2415 · Cited by 33 · cited 1×
“Meta-analyses and systemic reviews (154, 234, 241) show that the recipient outcomes of SLT are similar to those of primary LT with respect to overall and disease-free survival.”
ResultPreventative hepatology: minimising symptoms and optimising care
Hirschfield, G. M., Kumagi, T., & Heathcote, E. J. (2008) · Liver International · doi:10.1111/j.1478-3231.2008.01816.x · Cited by 32 · cited 2×
“Even though the half-life of oral acetaminophen is twice as long in patients with cirrhosis compared to healthy controls (473), significant hepatic injury is rare in patients with liver disease and/ or cirrhosis at a dosage of less than 4 g/day (473, 474).”
BackgroundLee, J. E. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i1.235 · Cited by 31 · cited 1×
“Cytotoxic chemotherapy can be considered in cases of HCC progression on sorafenib or drug intolerance (390-392).”
BackgroundLiving donor liver transplantation for recurrent hepatocellular carcinoma after liver resection
Kaido, T., Mori, A., Ogura, Y., Hata, K., Yoshizawa, A., Iida, T., Yagi, S., & Üemoto, S. (2011) · Surgery · doi:10.1016/j.surg.2011.06.032 · Cited by 28 · cited 2×
“The indications and selection criteria for salvage LDLT are same as those for primary LDLT (153, 236-239).”
BackgroundClinical Staging of Hepatocellular Carcinoma
Meier, V., & Ramadori, G. P. (2009) · Digestive Diseases · doi:10.1159/000218345 · Cited by 26 · cited 1×
“Although several staging systems for patients with HCC have been devised, there is no worldwide consensus (79).”
BackgroundKim, B. H., Park, J., Nam, B., Kwak, H. W., & Kim, W. R. (2014) · Liver International · doi:10.1111/liv.12519 · Cited by 23
Sugimachi, K., Shirabe, K., Taketomi, A., Soejima, Y., Iguchi, T., Takeishi, K., Toshima, T., Aishima, S., Tajima, T., & Maehara, Y. (2010) · Transplantation · doi:10.1097/tp.0b013e318208134e · Cited by 18 · cited 1×
“(167) also report poor diagnostic accuracy of radiologic imaging for small (< 1 cm) HCCs and their small effect on prognosis after LT.”
BackgroundPrevalence and Management of Pain by Different Age Groups of Korean Cancer Patients
Kim, J. Y., Jang, W. Y., Hur, M. H., Lee, K.-K., Do, Y. R., Park, K. U., Hong, Y. S., & SONG, H. S. (2012) · American Journal of Hospice and Palliative Medicine® · doi:10.1177/1049909112452624 · Cited by 16 · cited 1×
“The prevalence of pain in cancer patients ranges from 45% to 53% (454-456), and early aggressive palliative care including pain management could improve survival in lung cancer patients (457).”
BackgroundSung, P. S., Bae, S. H., Jang, J. W., Song, D. S., Kim, H. Y., Yoo, S. H., Park, C.-H., Kwon, J. H., Song, M. J., You, C. R., et al. (2011) · The Korean Journal of Hepatology · doi:10.3350/kjhep.2011.17.4.299 · Cited by 13
Cited by
Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study
Park, J., Chen, M., Colombo, M., Roberts, L. R., Schwartz, M., Chen, P., Kudo, M., Johnson, P., Wagner, S., Orsini, L. S., et al. (2015) · Liver International · doi:10.1111/liv.12818 · Cited by 1,245
Chernyak, V., Fowler, K. J., Kamaya, A., Kielar, A. Z., Elsayes, K. M., Bashir, M. R., Kono, Y., Do, R. K., Mitchell, D. G., Singal, A. G., et al. (2018) · Radiology · doi:10.1148/radiol.2018181494 · Cited by 1,152
Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis
Tang, A., Hallouch, O., Chernyak, V., Kamaya, A., & Sirlin, C. B. (2018) · Abdominal Radiology · doi:10.1007/s00261-017-1209-1 · Cited by 480
Korean Liver Cancer Association, K., & National Cancer Center, N. (2019) · Gut and Liver · doi:10.5009/gnl19024 · Cited by 391
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0294 · Cited by 343
Metadata
- Authors
- Korean Liver Cancer Study Group (KLCSG), & National Cancer Center, K. (.
- Venue
- Korean Journal of Radiology
- Publisher
- XMLink
- Published
- 2015
- Volume
- 16
- Issue
- 3
- Pages
- 465
- ISSN
- 1229-6929 (ISSN-L)
- 2005-8330
- OpenAlex
- W2561341815
- Cited by
- 201
- References
- 367
- FWCI
- 15.18
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.